We established a quick response research team to monitor the impacts of global pandemic COVID19 on this market to keep our clients informed about latest data and changing strategies. The report will incorporate these insight and data factors.
Global Vaccine Market Analysis By Group (Adult & Paediatric Vaccines) & By Type (Live Attenuated, Inactivated Vaccines, Subunit Vaccines & Next Generation Vaccines ) with Regional Outlook & Forecast to 2025
Vaccine market is relatively small and concentrated on supply and demand sides, in comparison to pharmaceuticals market. Global vaccine market is highly regulated and to a great extent reliant on on public purchasers and donor policies. With extremely distinct features, vaccine market comprise of complexities of assessing and understanding pricing and procurement. Vaccine market is comprised of individual markets for individual vaccine types each with their own specificities, particularly on the supply side.
Global Vaccine Market Segmentation
Vaccine Market, By Group
Vaccine Market, By Type
Live Attenuated Vaccines (Rotavirus, chickenpox, measles, mumps, BCG and rubella vaccines)
Inactivated Vaccines (Hepatitis A, influenza and polio vaccines)
Subunit Vaccines (Diphtheria, tetanus, pertussis, hepatitis B, human papillomavirus, Haemophilus influenzae type b, meningococcal, and pneumococcal vaccines)
Recombinant Vector Vaccines
Next Generation Vaccines (HIV, Ebola, Obesity, Plague, Obesity, etc)
Market Size & Forecat to 2025
The global vaccine market size reached USD 40.1 billion in 2017 and is expected to grow at a CAGR of 11.2% over the forecast period. The inactivated vaccines segment is expected to dominate the market while DNA vaccine has the potential to witness the fastest growth over the forecast period due mainly to the high specificity and the reduced risk of integration into the genome as compared to other traditional vaccines. Next generation vaccines (HIV, Ebola, Obesity, Plague, Obesity, etc) tends to rule the market in the future on the basis of technologies reviewed targeting delivery devices, packaging and formulation.
Regional Market Scenario
North America dominated the global human vaccines market in 2017, accounting for about 42.5% of the total revenue. High Income Countries (HICs) comprises 81.8% of global vaccine sales in terms of value, corresponding to about 20% of the annual volume of vaccines sold. Africa region is witnessing the considerable growth in vaccine market owing to the government regulations and investments from the major players. US vaccine market trends and opportunities are analyzed with insightful market data.
Drivers & Challenges to Market Growth
Demand side vaccine market drivers are governments of industrialized and developing countries, pooled procurement agencies, the private sector, and the various regulatory and advisory bodies overseeing vaccine quality and safety. Global vaccination rates tends to rise, however wide discrepancies will remain from region to region. For instance, almost 50 million infants worldwide had not been vaccinated against DPT3, with almost 75% of those living in India, China, Nigeria, Indonesia, Pakistan, Ethiopia, Congo, Sudan, Bangladesh, and the Philippines.
Value Chain Analysis
Immunization programmes require functional, end-to-end supply chain and logistics framework to be successful. While the vertically managed disease control programs work independently from primary health care supply system, managed by the central pharmaceutical and medical stores. Within the healthcare system, disease-specific program require the physical infrastructure for storing and transporting health products. Approx 50 low and middle income countries are deprived of logistic systems to meet internationally recognized World Health Organization (WHO) criteria of effective vaccine management.
Companies Analyzed in the Report
Major players of global vaccine market are BioFarma, Crucell, GlaxoSmithKline [GSK], Serum Institute of India, Ltd. [SIIL], Sanofi, Merck), Pfizer, Thai Red Cross. Recently, four-strain vaccine, known as a quadrivalent vaccine, Influvac Tetra developed by Mylan made available in New Zealand. In 2015, GlaxoSmithKline plc completed the acquisition of the vaccine business division of Novartis and received the approval for two new pediatric vaccines, Boostrix and Infanrixin India.
Next Generation Vaccine Platform
One vaccine is anticipated to cost USD 200 million and at least 10 years to be developed. The toughest challenges with the outbreak of Ebola and Zika, however, often lie in the timing and delivery that require a decade for inoculation. As far as innovations, companies are finding quicker ways to develop influenza vaccines using tobacco plants, insects, and nanoparticle systems, rather than relying on chicken eggs to incubate the virus and these methods hold the promise to save millions of dollars in development costs.
Global Vaccine Market Report Coverage & Deliverables
Complete review of the global vaccine market in 2017-2025, including adult and pediatric vaccines.
Market estimation for the pipeline vaccines, in addition with the prophylactics vaccine option in the future, successful business model for vaccine, major companies in this market, and possible new entrants
Market examination for vaccine manufacturing and production technologies along with focus on current production methods and new methods in development.